Efficacy of Metformin plus Sodium Glucose Transporter-2 inhibitors (SGLT-2i) in Obese Type 2
Year: 2024
Type: article
Abstract: Objective: To determine the efficacy of Metformin plus SGLT2 inhibitors in type 2 obese diabetic patients attending OPD at Liaquat University Hospital Hyderabad / Jamshoro. Methods: This quasi-experimental study was undertaken in the out-patient department of Liaquat University Hospital Hyderabad / Jamshoro from June 10th, 2022 to February 10th, 2023. All patients with type 2 DM for at least 8 months duration, already taking metformin with BMI ≥30kg/m2 and age limit from 30-55 years, of either gender were consecutively enrolled. SGLT2 inhibitors 10 mg once daily was added to Tab Metformin 500mg. The reduction in HbA1c of at least ≥0.5% from the baseline, at 6 months was considered as efficacy. Results: Of 114 patients, the mean age was 45.24 ±4.89 years. There were 76 (66.7%) males and 38 (33.3%) females. The mean weight, height, and BMI of the patients were 87.51 ±9.33 kg, 1.54 ±0.06 m, and 32.04 ±2.64 kg/m2 respectively. The mean pre and post HbA1c level were 9.78 ±1.43 and 8.73 ±1.39 respectively. 70 patients (61.4%) have shown reduction of HbA1c from 0.5 to 1.5% in 6 months, p-value was 0.002 significant in those with high A1c. Weight reduction was significant in both groups, BMI <30 p value 0.03 and in those BMI >30, p value was 0.02. Conclusion: The efficacy of Metformin plus SGLT2 inhibitors was found in more than half of the type 2 obese diabetic patients attending OPD at Liaquat University Hospital Hyderabad / Jamshoro
Authors: Asia Mazhar Shah, Nargis Khan, Imran Ali Shaikh, Naila Masood Siddiqui
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4402192539